Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$66.00 – $123.80
88% from low
Exchange
ARCX
ETF
Borrow rate
1.75%
Moderate
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| CUREDirexion Daily Healthcare Bull 3X ETF | $116.69 | +0.79% | $157M | — |
| APRWAllianzIM U.S. Equity Buffer20 Apr ETF | $37.05 | +0.21% | $199M | — |
| BJUNInnovator U.S. Equity Buffer ETF | $48.44 | +1.38% | $183M | — |
| CNRGState Street SPDR S&P Kensho Clean Power ETF | $109.56 | +2.58% | $202M | — |
| OALCOneAscent Large Cap Core ETF | $40.63 |
No company description on file.
No one on the platform currently holds CURE.
No tracked institution reports a position in CURE as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-23 | $0.3746 | 2026-06-30 |
| 2026-03-24 | $0.2832 | 2026-03-31 |
| 2025-12-23 | $0.2912 | 2025-12-31 |
| 2025-09-23 | $0.3101 | 2025-09-30 |
| 2025-06-24 | $0.3055 | 2025-07-01 |
| 2025-03-25 | $0.3455 | 2025-04-01 |
| 2024-12-23 | $0.1160 | 2024-12-31 |
| 2024-09-24 | $0.3329 | 2024-10-01 |
| 2024-06-25 | $0.2729 | 2024-07-02 |
| 2024-03-19 | $0.3555 | 2024-03-26 |
No one on the platform has traded CURE yet.
| +1.36% |
| $244M |
| — |
| OCTWAllianzIM U.S. Equity Buffer20 Oct ETF | $40.81 | +0.52% | $187M | — |
| OVLOverlay Shares Large Cap Equity ETF | $56.11 | +1.78% | $167M | — |
Source: Financial Modeling Prep · peers by sector/industry
| 2023-12-21 |
| $0.5727 |
| 2023-12-29 |
| 2023-09-19 | $0.4538 | 2023-09-26 |
| Execution date | Ratio |
|---|---|
| 2015-05-20 | 5-for-1 |
| 2013-08-20 | 2-for-1 |
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$CURE $XLV strong move over the past 3 mos. Now a 71 RSI, and the risk/reward has flipped. Closed the overhead gap at 160.20. Reallocating and sold some of my position.
View on StockTwits ↗If Insiders are buying Health Care $XLV, you should be too? $AMGN $CURE $IBB $UNH
View on StockTwits ↗21 Best Leveraged Equity ETFs SOXL = Direxion Daily Semiconductor Bull 3X ETF TQQQ - ProShares UltraPro QQQ TECL - Direxion Daily Technology Bull 3X ETF USD - ProShares Ultra Semiconductors QLD - ProShares Ultra QQQ ROM - ProShares Ultra Technology UPRO - ProShares UltraPro S&P500 SPXL - Direxion Daily S&P500 Bull 3X ETF SPUU - Direxion Daily S&P 500 Bull 2X ETF UDOW - ProShares UltraPro Dow30 $SSO - ProShares Ultra S&P500 $CURE - Direxion Daily Healthcare Bull 3X ETF $RXL - ProShares Ultra Health Care $UCC - ProShares Ultra Consumer Discretionary $DDM - ProShares Ultra Dow30 UXI - ProShares Ultra Industrials MIDU - Direxion Daily Mid Cap Bull 3X ETF UMDD - ProShares UltraPro MidCap400 BIB - ProShares Ultra Nasdaq Biotechnology UGE - ProShares Ultra Consumer Staples TNA - Direxion Daily Small Cap Bull 3X ETF https://x.com/MicahMcDonald8/status/2060947289037033584?s=20
View on StockTwits ↗$DTIL $BEAM $CRSP $BMRN $CURE So for Gene Therapy companies, this is a breakthrough and yet another validation: "There has never been a treatment that could directly target and eliminate the root source of hepatitis B viral replication and now there is. " $DTIL announces this huge news and as of the market open it's not even visible on Yahoo Finance. -> Data was presented by was presented by Man Fung Yuen MD, Ph.D., Chair Professor of The University of Hong Kong and Li Shu Fan Medical Foundation Professor in Medicine, and the Chief of the Division of Gastroenterology and Hepatology, Queen Mary Hospital, Hong Kong. He is one of the top internationally renowned researchers in the field of hepatitis B disease. He has now published more than 630 papers in world-renowned medical journals including New England Journal of Medicine, Lancet, Nature Medicine, Lancet Infectious Diseases and Lancet Oncology. He has delivered more than 360 lectures all over the world.
View on StockTwits ↗$XLV / $CURE looking more bullish these days. Always good to look elsewhere when leading sectors are taking a breather. Cycles are good (3 of 4 near lows). Price printing higher lows though in a downtrend. Stochastics earlier buy signal in play. MACD buy signal. Yeah, not bad. Very strong this week...
View on StockTwits ↗$XLV $CURE started a position here - high quality basket of health care, including Eli Lilly, J&J and Merck. It’s rare to get this at just a 24 RSI, so am taking the discount. Below the 200ma now but still above the bottom bollinger - will DCA on additional weakness.
View on StockTwits ↗$CURE: safe haven space showing rounded bottom pullback and breakout.
View on StockTwits ↗$CURE Current Stock Price: $114.91 Contracts to trade: $115.0 CURE Feb 20 2026 Call Entry: $3.10 Exit: $5.95 ROI: 92% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$DFEN $DUSL $CURE quite the run off of 2025 April lows. Massive. Sidelined in these trading vehicles 🚗
View on StockTwits ↗$RNAZ other cancer companies trying to short, but will lose their shirt on FDA approval!!! $NVO $CURE $LLY
View on StockTwits ↗16 Leveraged Equity ETFs that don't Suck (yes, all the rest do) 6. $UPRO - ProShares UltraPro S&P500 3X 7. $ROM - ProShares Ultra Technology 2X 8. $SPXL - Direxion Daily S&P 500 Bull 3X Shares 9. $SPUU - Direxion Daily S&P 500 Bull 2X Shares 10. $CURE - Direxion Daily Healthcare Bull 3X Shares Chart dates 6/6/2014 thru 1/2/2026
View on StockTwits ↗$DOCS $CURE $LLY $MRNA leading healthcare today. Just waiting for $UNH to rally to $375+. :-)
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.